Kevin Joseph Fitzgerald sold $669k of ALNY
CSO & EVP, Head of Research at ALNYLAM PHARMACEUTICALS, INC.. 2,755 shares at an average of $242.94, traded Mar 3, 2025, filed Mar 5, 2025.
Score components
- +15RoleOfficer
- +20Trade size$669k at market
- +5Share of holdings soldSold 17% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-25-000034, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 3, 2025 | AGrant or award Common Stock10b5-1 | +3,871 | $0.00 | $0 | 16,256 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -204 | $242.37 | $49k | 16,052 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -224 | $243.36 | $55k | 15,828 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -151 | $244.41 | $37k | 15,677 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -111 | $245.26 | $27k | 15,566 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -45 | $246.18 | $11k | 15,521 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -4 | $247.35 | $989 | 15,517 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -1 | $248.36 | $248 | 15,516 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -465 | $242.69 | $113k | 15,051 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -487 | $243.94 | $119k | 14,564 | Mar 5, 2025 |
| Mar 3, 2025 | SOpen-market sale Common Stock10b5-1 | -219 | $245.30 | $54k | 14,345 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -121 | $239.24 | $29k | 14,224 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -328 | $240.95 | $79k | 13,896 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -324 | $241.68 | $78k | 13,572 | Mar 5, 2025 |
| Mar 4, 2025 | SOpen-market sale Common Stock10b5-1 | -71 | $242.93 | $17k | 13,501 | Mar 5, 2025 |
| Mar 3, 2025 | AGrant or award Stock Option (right to buy)derivative10b5-1 | +7,819 | $0.00 | $0 | 7,819 | Mar 5, 2025 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 35Weak | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $16M 50,937 shares | -63% | |
| 15Weak | ALNYLAM PHARMACEUTICALS, INC. | Michael W Bonney director | $3.1M 11,250 shares | -40% | |
| 23Weak | ALNYbuy ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $10k 36 shares | - | |
| 45Moderate | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Colleen F Reitan director | $8,383 36 shares | -100% | |
| 33Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $2.2M 7,440 shares | -98% | |
| 23Weak | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg CMO & EVP Dev & Med Affairs | $2.9M 9,766 shares | -40% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $945k 3,877 shares | -4% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $308k 1,264 shares | -3% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg CMO & EVP Dev & Med Affairs | $621k 2,557 shares | -9% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.